Hepatic Vein Thrombosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome.
|
28710306 |
2017 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Here, a 22 year old female with angiographically proven BCS secondary to JAK2/V617F positive Polycythemia vera on therapeutic warfarin presented with acute liver failure (ALF).
|
26626649 |
2016 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to evaluate the association of factor V Leiden (FVL), Janus kinase 2 (JAK2), prothrombin, and methylene tetrahydrofolate reductase (MTHFR) mutations with primary BCS.
|
26238013 |
2016 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
ORPHANET |
Association between JAK2 rs4495487 Polymorphism and Risk of Budd-Chiari Syndrome in China.
|
26557140 |
2015 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Analysis of JAK2 mutation in the patients with idiopathic PVT or BCS showed that 20% had latent MPNs.
|
25698270 |
2015 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients.
|
23980667 |
2014 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The incidence and clinical outcomes of JAK2 mutations, novel ten-eleven translocation 2 (TET2) mutations, and the 46/1 haplotype in BCS are unknown for liver transplantation (LT).
|
22467227 |
2012 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis.
|
21364191 |
2011 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe a young woman presenting with idiopathic eosinophilia, JAK2 mutation, and BCS.
|
21264914 |
2011 |
Hepatic Vein Thrombosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The presence of JAK2V617F in both ECs and hematopoietic cells belonging to BCS patients with PV indicates that ECs from these patients are involved by the malignant process and that in this subpopulation of patients the disease may originate from a cell common to hematopoietic and endothelial cells.
|
21761323 |
2011 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the JAK2-V617F mutation occurs after the onset of monoclonal haematopoiesis; thus the V617F mutation of JAK2 may not be the primary event in the induction of BCS.
|
19308656 |
2009 |
Hepatic Vein Thrombosis
|
0.600 |
Biomarker
|
disease |
CTD_human |
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome.
|
19293426 |
2009 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Determination of the JAK2 V617F mutation may be useful to recognize patients with Budd-Chiari syndrome with or at risk for the subsequent development of overt myeloproliferative diseases.
|
18600100 |
2008 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
By resolving the sensitivity bias of the JAK2 mutation with the results of BM histology and clonality assay, CMPD was diagnosed in 53% of patients with EHPVO or BCS.
|
17133457 |
2006 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A clonal mutation in JAK2 tyrosine kinase (JAK2V617F) occurs in a high proportion of patients with MPD and is of use in the characterization of latent MPD in BCS.
|
16762626 |
2006 |
Hepatic Vein Thrombosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to use JAK2 V617F analysis to re-evaluate the validity of elevated Epo levels as a PV-exclusion criterion in patients with hepatic vein thrombosis [Budd-Chiari syndrome (BCS)].
|
16827884 |
2006 |
Hepatic Vein Thrombosis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
|
16762626 |
2006 |